AU2003226012B2 - Methods of virus production - Google Patents

Methods of virus production Download PDF

Info

Publication number
AU2003226012B2
AU2003226012B2 AU2003226012A AU2003226012A AU2003226012B2 AU 2003226012 B2 AU2003226012 B2 AU 2003226012B2 AU 2003226012 A AU2003226012 A AU 2003226012A AU 2003226012 A AU2003226012 A AU 2003226012A AU 2003226012 B2 AU2003226012 B2 AU 2003226012B2
Authority
AU
Australia
Prior art keywords
temperature
virus
adenovirus
culture
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2003226012A
Other languages
English (en)
Other versions
AU2003226012A1 (en
Inventor
Charles F. Goochee
Liangzhi Xie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck Sharp and Dohme Ltd
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme Ltd, Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme Ltd
Publication of AU2003226012A1 publication Critical patent/AU2003226012A1/en
Application granted granted Critical
Publication of AU2003226012B2 publication Critical patent/AU2003226012B2/en
Assigned to MERCK SHARP & DOHME CORP. reassignment MERCK SHARP & DOHME CORP. Request to Amend Deed and Register Assignors: MERCK & CO., INC.
Assigned to MERCK SHARP & DOHME CORP. reassignment MERCK SHARP & DOHME CORP. Request to Amend Deed and Register Assignors: MERCK & CO., INC.
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2003226012A 2002-03-29 2003-03-27 Methods of virus production Ceased AU2003226012B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36865402P 2002-03-29 2002-03-29
US60/368,654 2002-03-29
PCT/US2003/009269 WO2003085138A1 (en) 2002-03-29 2003-03-27 Methods of virus production

Publications (2)

Publication Number Publication Date
AU2003226012A1 AU2003226012A1 (en) 2003-10-20
AU2003226012B2 true AU2003226012B2 (en) 2007-05-24

Family

ID=28791896

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003226012A Ceased AU2003226012B2 (en) 2002-03-29 2003-03-27 Methods of virus production

Country Status (9)

Country Link
US (1) US7344873B2 (enExample)
EP (1) EP1492891B1 (enExample)
JP (1) JP4413012B2 (enExample)
AT (1) ATE386824T1 (enExample)
AU (1) AU2003226012B2 (enExample)
CA (1) CA2478901A1 (enExample)
DE (1) DE60319210T2 (enExample)
ES (1) ES2299715T3 (enExample)
WO (1) WO2003085138A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8426124B2 (en) * 2007-05-04 2013-04-23 Baxter International Inc. Two-step temperature profile for the propagation of viruses
WO2011130119A2 (en) 2010-04-14 2011-10-20 Millipore Corporation Methods of producing high titer, high purity virus stocks and methods of use thereof
US20110262965A1 (en) 2010-04-23 2011-10-27 Life Technologies Corporation Cell culture medium comprising small peptides
US9879229B2 (en) 2011-03-14 2018-01-30 National Research Council Of Canada Method of viral production in cells

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3962424A (en) * 1974-01-31 1976-06-08 Recherche Et Industrie Therapeutiques (R.I.T.) Live brovine adenovirus vaccines, preparation thereof and method of vaccination using them
US5618714A (en) 1993-12-15 1997-04-08 Eli Lilly And Company Methods for producing protein C
US5837520A (en) * 1995-03-07 1998-11-17 Canji, Inc. Method of purification of viral vectors
DE69638058D1 (de) * 1995-06-15 2009-11-26 Crucell Holland Bv Verpackungssysteme für humane rekombinante Adenoviren zur Gentherapie
CA2378539A1 (en) 1999-07-06 2001-01-11 Merck & Co., Inc. Adenovirus carrying gag gene hiv vaccine
CA2422882A1 (en) 2000-09-15 2002-03-21 Merck & Co., Inc. Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol, nef and modifications

Also Published As

Publication number Publication date
US7344873B2 (en) 2008-03-18
US20050176146A1 (en) 2005-08-11
EP1492891B1 (en) 2008-02-20
JP4413012B2 (ja) 2010-02-10
AU2003226012A1 (en) 2003-10-20
DE60319210T2 (de) 2009-02-12
ES2299715T3 (es) 2008-06-01
EP1492891A4 (en) 2005-08-24
EP1492891A1 (en) 2005-01-05
JP2005521423A (ja) 2005-07-21
CA2478901A1 (en) 2003-10-16
WO2003085138A1 (en) 2003-10-16
ATE386824T1 (de) 2008-03-15
DE60319210D1 (de) 2008-04-03

Similar Documents

Publication Publication Date Title
Nadeau et al. Production of adenovirus vector for gene therapy
ES2532015T3 (es) Método para la producción de vectores adenovíricos
Dormond et al. From the first to the third generation adenoviral vector: what parameters are governing the production yield?
Sanders et al. PER. C6® cells as a serum-free suspension cell platform for the production of high titer poliovirus: A potential low cost of goods option for world supply of inactivated poliovirus vaccine
JP2013165736A (ja) ウイルス産生プロセス
CN102762721A (zh) 用于生产Ad26腺病毒载体的方法
US20120315696A1 (en) METHOD FOR THE PRODUCTION OF Ad26 ADENOVIRAL VECTORS
Shen et al. Process optimization and scale-up for production of rabies vaccine live adenovirus vector (AdRG1. 3)
Xie et al. Large‐scale propagation of a replication‐defective adenovirus vector in stirred‐tank bioreactor PER. C6™ cell culture under sparging conditions
Léon et al. The EB66® cell line as a valuable cell substrate for MVA-based vaccines production
JP2015535687A (ja) 新規ｍｖａウイルス及びその使用
WO2021139147A1 (zh) 一种腺病毒二价疫苗
AU2003226012B2 (en) Methods of virus production
Silva et al. Scalable culture systems using different cell lines for the production of Peste des Petits ruminants vaccine
Liu et al. Enhancing enterovirus A71 vaccine production yield by microcarrier profusion bioreactor culture
US20090253184A1 (en) Compositions and methods related to an adenoviral trans-complementing cell line
CN111440770A (zh) 人源细胞悬浮培养的培养基组合及溶瘤痘苗病毒的制备方法
Ferreira et al. Two different serum-free media and osmolality effect upon human 293 cell growth and adenovirus production
CN104087549B (zh) 高产杆状病毒的昆虫细胞系及其应用
Fernandes et al. Upstream bioprocess for adenovirus vectors
Trabelsi et al. Development of an efficient veterinary rabies vaccine production process in the avian suspension cell line AGE1. CR. pIX
TW202237831A (zh) 生產腺病毒之方法
Subramanian et al. Scaleable production of adenoviral vectors by transfection of adherent PER. C6 cells
McIntosh et al. Growth of a clonal cell line of Helicoverpa zea (Lepidoptera: Noctuidae) in suspension culture and replication of its homologous baculovirus HzSNPV
CN1231598C (zh) 一种重组禽腺病毒的制备方法

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE PATENTEE NAME FROM MERCK & CO., INC. TO MERCK SHARP & DOHME CORP.

MK14 Patent ceased section 143(a) (annual fees not paid) or expired